Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor for prevention of liver carcinogenesis

Journal of Carcinogenesis

Volumn 11, Issue , 2012, Pages

  Shimizu, Masahito ^a   Shirakami, Yohei ^a   Imai, Kenji ^a   Takai, Koji ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acyclic retinoid; chemoprevention; clonal deletion and inhibition; combination therapy; HCC; RXR phosphorylation

Indexed keywords

ACYCLIC RETINOID; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LECTIN REACTIVE A FETOPROTEIN FACTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN; PROTEIN KINASE B; RETINOID; RETINOID X RECEPTOR ALPHA; RETINOL; UNCLASSIFIED DRUG; VALPROIC ACID;

ALBUMINURIA; ARTICLE; BASIC RESEARCH; CANCER PREVENTION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHOLESTEROL METABOLISM; CLINICAL RESEARCH; DRUG INDUCED HEADACHE; HUMAN; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LONG TERM CARE; NONHUMAN; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84872736591     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.100398     Document Type: Article

References (80)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
3. Parikh S, Hyman D. Hepatocellular cancer: A guide for the internist. Am J Med 2007;120:194-202. (Pubitemid 46341174)
4. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, et al. Meta-analysis: The efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011;33:1104-12.
5. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. J Hepatol 2010;52:889-94.
6. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: Interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010;17:287-92.
7. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006;35:204-14.
8. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561-7. (Pubitemid 26177483)
9. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-7. (Pubitemid 29157643)
10. Takai K, Okuno M, Yasuda I, Matsushima-Nishiwaki R, Uematsu T, Tsurumi H, et al. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology 2005;48:39-45. (Pubitemid 40529209)
11. Moriwaki H, Shimizu M, Okuno M, Nishiwaki-Matsushima R. Chemoprevention of liver carcinogenesis with retinoids: Basic and clinical aspects. Hepatol Res 2007;37 Suppl 2:S299-302.
12. Shimizu M, Takai K, Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: Phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 2009;100:369-74.
13. Shimizu M, Sakai H, Moriwaki H. Chemoprevention of hepatocellular carcinoma by acyclic retinoid. Front Biosci 2011;16:759-69.
14. Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001;61:7675-82. (Pubitemid 32995065)
15. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54. (Pubitemid 26285969)
16. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International union of pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760-72. (Pubitemid 44833744)
17. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International union of pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 2006;58:712-25. (Pubitemid 44833741)
18. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006;58:726-41. (Pubitemid 44833742)
19. Okuno M, Kojima S, Akita K, Matsushima-Nishiwaki R, Adachi S, Sano T, et al. Retinoids in liver fibrosis and cancer. Front Biosci 2002;7:d204-18.
20. Shirakami Y, Lee SA, Clugston RD, Blaner WS. Hepatic metabolism of retinoids and disease associations. Biochim Biophys Acta 2012;1821:124-36.
21. Leo MA, Lieber CS. Hepatic vitamin A depletion in alcoholic liver injury. N Engl J Med 1982;307:597-601. (Pubitemid 12043963)
22. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-69. (Pubitemid 351615417)
23. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18. (Pubitemid 40385459)
24. Clemente C, Elba S, Buongiorno G, Berloco P, Guerra V, Di Leo A. Serum retinol and risk of hepatocellular carcinoma in patients with child-Pugh class A cirrhosis. Cancer Lett 2002;178:123-9. (Pubitemid 34178536)
25. Newsome PN, Beldon I, Moussa Y, Delahooke TE, Poulopoulos G, Hayes PC, et al. Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. Aliment Pharmacol Ther 2000;14:1295-301.
26. Yanagitani A, Yamada S, Yasui S, Shimomura T, Murai R, Murawaki Y, et al. Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 2004;40:366-75. (Pubitemid 39062854)
27. Wan YJ, Cai Y, Lungo W, Fu P, Locker J, French S, et al. Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice. J Biol Chem 2000;275:28285-90.
28. Gyamfi MA, Tanaka Y, He L, Klaassen CD, Wan YJ. Hepatic effects of a methionine-choline-deficient diet in hepatocyte RXRalpha-null mice. Toxicol Appl Pharmacol 2009;234:166-78.
29. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93. (Pubitemid 33741893)
30. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810. (Pubitemid 47504871)
31. Muto Y, Moriwaki H. Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 1984;73:1389-93. (Pubitemid 15243582)
32. Lee JH, Yoon JH, Yu SJ, Chung GE, Jung EU, Kim HY, et al. Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. Cancer Lett 2010;295:229-35.
33. Shirakami Y, Gottesman ME, Blaner WS. Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin: Retinol acyltransferase- deficient mice primarily through retinoid actions immediately after carcinogen administration. Carcinogenesis 2012;33:268-74.
34. de The H, Marchio A, Tiollais P, Dejean A. A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma. Nature 1987;330:667-70. (Pubitemid 18005585)
35. Sever CE, Locker J. Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol Carcinog 1991;4:138-44.
36. Li C, Wan YJ. Differentiation and antiproliferation effects of retinoic acid receptor beta in hepatoma cells. Cancer Lett 1998;124:205-11. (Pubitemid 28073689)
37. Wan YJ, Wang L, Wu TC. Expression of retinoic acid receptor genes in developing rat livers and hepatoma cells. Lab Invest 1992;66:646-51.
38. Ando N, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Tanaka T, et al. Expression of retinoid X receptor alpha is decreased in 3-methyl-4-dimethylaminoazobenzene-induced hepatocellular carcinoma in rats. Oncol Rep 2007;18:879-84.
39. Yan TD, Wu H, Zhang HP, Lu N, Ye P, Yu FH, et al. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res 2010;70:2285-95.
40. Han YH, Zhou H, Kim JH, Yan TD, Lee KH, Wu H, et al. A unique cytoplasmic localization of retinoic acid receptor-gamma and its regulations. J Biol Chem 2009;284:18503-14.
41. Garcia AD, Ostapchuk P, Hearing P. Functional interaction of nuclear factors EF-C, HNF-4, and RXR alpha with hepatitis B virus enhancer I. J Virol 1993;67:3940-50. (Pubitemid 23180718)
42. Matsushima-Nishiwaki R, Shidoji Y, Nishiwaki S, Yamada T, Moriwaki H, Muto Y. Aberrant metabolism of retinoid X receptor proteins in human hepatocellular carcinoma. Mol Cell Endocrinol 1996;121:179-90. (Pubitemid 26394727)
43. Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003;24:1353-9. (Pubitemid 37038825)
44. Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, et al. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. Cancer Sci 2007;98:1868-74. (Pubitemid 350002191)
45. Adachi S, Okuno M, Matsushima-Nishiwaki R, Takano Y, Kojima S, Friedman SL, et al. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 2002;35:332-40. (Pubitemid 34106372)
46. Moriwaki H, Muto Y, Ninomiya M, Kawai K, Suzuki Y, Seto T. Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3-methyl-N, N-dimethyl-4-aminoazobenzene. Gastroenterol Jpn 1988;23:546-52. (Pubitemid 18264785)
47. Kagawa M, Sano T, Ishibashi N, Hashimoto M, Okuno M, Moriwaki H, et al. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. Carcinogenesis 2004;25:979-85. (Pubitemid 38898636)
48. Sano T, Kagawa M, Okuno M, Ishibashi N, Hashimoto M, Yamamoto M, et al. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer 2005;51:197-206. (Pubitemid 40734720)
49. Shimizu M, Sakai H, Shirakami Y, Iwasa J, Yasuda Y, Kubota M, et al. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J-(db)/Lepr(db) mice. Cancer Prev Res (Phila) 2011;4:128-36.
50. Araki H, Shidoji Y, Yamada Y, Moriwaki H, Muto Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem Biophys Res Commun 1995;209:66-72.
51. Yamada Y, Shidoji Y, Fukutomi Y, Ishikawa T, Kaneko T, Nakagama H, et al. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994;10:151-8. (Pubitemid 24257510)
52. Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, et al. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. Cancer Sci 2007;98:431-7. (Pubitemid 46195617)
53. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, et al. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 2009;285:210-7.
54. Fukutomi Y, Omori M, Muto Y, Ninomiya M, Okuno M, Moriwaki H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/PRF/5). Jpn J Cancer Res 1990;81:1281-5.
55. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Muto Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995;207:382-8.
56. Nakamura N, Shidoji Y, Moriwaki H, Muto Y. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha. Biochem Biophys Res Commun 1996;219:100-4. (Pubitemid 26071610)
57. Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, et al. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002;36:660-71. (Pubitemid 34499404)
58. Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, et al. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 2002;36:1115-24. (Pubitemid 35253427)
59. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002;62:3997-4006. (Pubitemid 34791066)
60. Shimizu M, Suzui M, Deguchi A, Lim JT, Xiao D, Hayes JH, et al. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells. Clin Cancer Res 2004;10:6710-21. (Pubitemid 39346569)
61. Suzui M, Shimizu M, Masuda M, Lim JT, Yoshimi N, Weinstein IB. Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther 2004;3:309-16. (Pubitemid 39193706)
62. Tatsukawa H, Sano T, Fukaya Y, Ishibashi N, Watanabe M, Okuno M, et al. Dual induction of caspase 3-and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer 2011;10:4.
63. Komi Y, Sogabe Y, Ishibashi N, Sato Y, Moriwaki H, Shimokado K, et al. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab Invest 2010;90:52-60.
64. Shimizu M, Suzui M, Deguchi A, Lim JT, Weinstein IB. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin Cancer Res 2004;10:1130-40. (Pubitemid 38198915)
65. Shao RX, Otsuka M, Kato N, Taniguchi H, Hoshida Y, Moriyama M, et al. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 2005;128:86-95. (Pubitemid 40039961)
66. Nakagawa T, Shimizu M, Shirakami Y, Tatebe H, Yasuda I, Tsurumi H, et al. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett 2009;273:250-6.
67. Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, et al. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. J Clin Oncol 2010;28 Suppl 15:abstr 4024.
68. Okusaka T, Makuuchi M, Matsui O, Kumada H, Tanaka K, Kaneko S, et al. Clinical benefit of peretinoin for the suppression of hepatocellular carcinoma (HCC) recurrence in patients with Child-Pugh grade A (CP-A) and small tumor: A subgroup analysis in a phase II/III randomized, placebo-controlled trial. J Clin Oncol 2011, 29 Suppl 4: abstr 165.
69. Okusaka T, Ueno H, Ikeda M, Morizane C. Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res 2011;41:542-52.
70. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92. (Pubitemid 27014990)
71. Koda M, Murawaki Y, Mitsuda A, Ohyama K, Horie Y, Suou T, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000;88:529-37. (Pubitemid 30056925)
72. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801. (Pubitemid 23174709)
73. Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994;106:1618-24. (Pubitemid 24163135)
74. Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y. Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: A potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 1997;3:727-31. (Pubitemid 27244339)
75. Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res 2008;14:2806-12.
76. Kitagawa J, Hara T, Tsurumi H, Ninomiya S, Ogawa K, Adachi S, et al. Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2. J Cancer Res Clin Oncol 2011;137:779-87.
77. Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, et al. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 2007;56:1557-63. (Pubitemid 350033194)
78. Shimizu M, Moriwaki H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment. PPAR Res 2008;2008:181047.
79. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8. (Pubitemid 38182303)
80. Kamimura T, Miyamoto T, Harada M, Akashi K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci 2011;102:1929-37.